ArQule, Inc. (ARQL)
(Delayed Data from NSDQ)
$6.51 USD
+0.23 (3.66%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.50 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[ARQL]
Reports for Purchase
Showing records 1 - 20 ( 50 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Acquisition by Merck Announced; Lowering Rating to Neutral, Raising PT to Merck?s $20 Bid
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Healthcare - ASH 2019: Don''t Miss Our KOL Event Series at ASH!
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
Healthcare - ASH 2019: Meet the Doctors Who Will Speak at Our KOL Event Series
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
ASH 2019: Keep Your Eyes Peeled For These Presentations!
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
Save The Date: KOL Events at ASH on December 9, 2019 in Orlando, FL
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
ARQ 531 ASH Abstract Data Positive, But Competition Heats up
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
3Q19 - Anticipation Builds For ASH. ''531 Durability Data Are Important.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
3Q19 Results; Looking to ASH for More ARQ 531 Data and FDA Guidance
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Industry: Medical - Drugs
Co-Investment Accelerator Program Established; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Aiming for Success With Precision Drugs in Both
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Industry: Medical - Drugs
Q219 - Anticipation Builds For Comprehensive ''531 Update In Late-2019
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Drugs
After Sharpening Our Pencil on the ''531 Model We Are Increasing PT to $18
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T